Extra-hepatic isozymes from the CYP1 and CYP2 families as potential chemotherapeutic targets

Current Topics in Medicinal Chemistry

Volumn 13, Issue 12, 2013, Pages 1441-1453

  Raccor, Brianne S ^a   Kaspera, Rüdiger ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Angiogenesis; Carcinogenesis; Chemotherapeutic; Cytochrome P450; Hypoxia; Pharmacogenetics

Indexed keywords

5 FLUORO 2 (4 LYSYLAMINO 3 METHYLPHENYL)BENZOTHIAZOLE; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; BANOXANTRONE; BENZO [A] PYRENE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; CYTOCHROME P450 1; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DOCETAXEL; EPOXYICOSATRIENOIC ACID; ETHOXYRESORUFIN; FARNESOID X RECEPTOR; FLUTAMIDE; GLUTATHIONE TRANSFERASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PACLITAXEL; PREGNANE X RECEPTOR; RETINOID X RECEPTOR; TIRAPAZAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; ENZYME ACTIVITY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENETIC POLYMORPHISM; HEAD AND NECK CANCER; HORMONE SYNTHESIS; HUMAN; HYPOXIA; LIVER CELL CARCINOMA; META ANALYSIS (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); POINT MUTATION; PROTEIN EXPRESSION; REVIEW; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; MICROSOMES, LIVER; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84881354459     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313120006     Document Type: Review

References (141)

1. Guengerich, F.P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J., 2006, 8(1), E101-111.
2. Fleming, I. The cytochrome P450 pathway in angiogenesis and endothelial cell biology. Cancer Metast. Rev., 2011, 30(3-4), 541-555.
3. Payne, A.H.; Hales, D.B. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr. Rev., 2004, 25(6), 947-970.
4. Katagiri, M.; Kagawa, N.; Waterman, M.R. The role of cytochrome b5 in the biosynthesis of androgens by human P450c17. Arch. Biochem. Biophys., 1995, 317(2), 343-347.
5. Simpson, E.R.; Mahendroo, M.S.; Means, G.D.; Kilgore, M.W.; Hinshelwood, M.M.; Graham-Lorence, S.; Amarneh, B.; Ito, Y.; Fisher, C.R.; Michael, M.D.; et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev., 1994, 15(3), 342-355.
6. Schuster, I.; Bernhardt, R. Inhibition of cytochromes p450: existing and new promising therapeutic targets. Drug Metab. Rev., 2007, 39(2-3), 481-499.
7. Jordan, V.C.; Brodie, A.M. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids, 2007, 72(1), 7-25.
8. Attard, G.; Reid, A.H.; Olmos, D.; de Bono, J.S. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res., 2009, 69(12), 4937-4940.
9. Murray, G.I.; Taylor, M.C.; McFadyen, M.C.; McKay, J.A.; Greenlee, W.F.; Burke, M.D.; Melvin, W.T. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res., 1997, 57(14), 3026-3031.
10. Jiang, J.G.; Chen, C.L.; Card, J.W.; Yang, S.; Chen, J.X.; Fu, X.N.; Ning, Y.G.; Xiao, X.; Zeldin, D.C.; Wang, D.W. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res., 2005, 65(11), 4707-4715.
11. McFadyen, M.C.; McLeod, H.L.; Jackson, F.C.; Melvin, W.T.; Doehmer, J.; Murray, G.I. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem. Pharmacol., 2001, 62(2), 207-212.
12. Cavalieri, E.L.; Rogan, E.G. Depurinating estrogen-DNA adducts in the etiology and prevention of breast and other human cancers. Future Oncol., 2010, 6(1), 75-91.
13. Nebert, D.W.; Dalton, T.P. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat. Rev. Cancer, 2006, 6, 947-960.
14. Zhou, S.F.; Liu, J.P.; Chowbay, B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev., 2009, 41(2), 89-295.
15. Tang, Y.M.; Chen, G.F.; Thompson, P.A.; Lin, D.X.; Lang, N.P.; Kadlubar, F.K. Development of an antipeptide antibody that binds to the C-terminal region of human CYP1B1. Drug Metab. Dispos., 1999, 27(2), 274-280.
16. Androutsopoulos, V.P.; Tsatsakis, A.M.; Spandidos, D.A. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer, 2009, 9.
17. Murray, G.I.; Melvin, W.T.; Greenlee, W.F.; Burke, M.D. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu. Rev. Pharmacol. Toxicol., 2001, 41, 297-316.
18. Tsuchiya, Y.; Nakajima, M.; Kyo, S.; Kanaya, T.; Inoue, M.; Yokoi, T. Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res., 2004, 64(9), 3119-3125.
19. Kim, J.H.; Sherman, M.E.; Curriero, F.C.; Guengerich, F.P.; Strickland, P.T.; Sutter, T.R. Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol. Appl. Pharmacol., 2004, 199(3), 210-219.
20. Sissung, T.M.; Price, D.K.; Sparreboom, A.; Figg, W.D. Pharmacogenetics and regulation of human cytochrome P450 1B1: Implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol. Cancer Res., 2006, 4(3), 135-150.
21. Zhang, Y.; Gaikwad, N.W.; Olson, K.; Zahid, M.; Cavalleri, E.L.; Rogan, E.G. Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism, 2007, 56(7), 887-894.
22. Bruno, R.D.; Njar, V.C. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg. Med. Chem., 2007, 15(15), 5047-5060.
23. Rendic, S.; Guengerich, F.P. Contributions of human enzymes in carcinogen metabolism. Chem. Res. Toxicol., 2012, 25(7), 1316-1383.
24. Shimada, T.; Fujii-Kuriyama, Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci., 2004, 95(1), 1-6.
25. Ma, Q. Xenobiotic-activated receptors: from transcription to drug metabolism to disease. Chem. Res. Toxicol., 2008, 21(9), 1651-1671.
26. Kaspera, R.; Naraharisetti, S.B.; Evangelista, E.A.; Marciante, K.D.; Psaty, B.M.; Totah, R.A. Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem. Pharmacol., 2011, 82(6), 681-691.
27. Sergentanis, T.N.; Economopoulos, K.P. Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res. Treat., 2010, 122(2), 459-469.
28. Salinas-Sanchez, A.S.; Donate-Moreno, M.J.; Lopez-Garrido, M.P.; Gimenez-Bachs, J.M.; Escribano, J. Role of CYP1B1 gene polymorphisms in bladder cancer susceptibility. J. Urol., 2012, 187(2), 700-706.
29. Trubicka, J.; Grabowska-Klujszo, E.; Suchy, J.; Masojc, B.; Serrano-Fernandez, P.; Kurzawski, G.; Cybulski, C.; Gorski, B.; Huzarski, T.; Byrski, T.; Gronwald, J.; Zlowocka, E.; Kladny, J.; Banaszkiewicz, Z.; Wisniowski, R.; Kowalska, E.; Lubinski, J.; Scott, R.J. Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility. BMC Cancer, 2010, 10, 420.
30. Spurr, N.K.; Gough, A.C.; Stevenson, K.; Wolf, C.R. Msp-1 polymorphism detected with a cDNA probe for the P-450 I family on chromosome 15. Nucleic Acids Res., 1987, 15(14), 5901.
31. Landi, M.T.; Bertazzi, P.A.; Shields, P.G.; Clark, G.; Lucier, G.W.; Garte, S.J.; Cosma, G.; Caporaso, N.E. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics, 1994, 4(5), 242-246.
32. Hirvonen, A.; Husgafvel-Pursiainen, K.; Karjalainen, A.; Anttila, S.; Vainio, H. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol. Biomarkers Prev., 1992, 1(6), 485-489.
33. Hayashi, S.; Watanabe, J.; Nakachi, K.; Kawajiri, K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J. Biochem., 1991, 110(3), 407-411.
34. Kisselev, P.; Schunck, W.H.; Roots, I.; Schwarz, D. Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone. Cancer Res., 2005, 65(7), 2972-2978.
35. Cascorbi, I.; Brockmoller, J.; Roots, I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res., 1996, 56(21), 4965-4969.
36. Smart, J.; Daly, A.K. Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics, 2000, 10(1), 11-24.
37. Zhan, P.; Wang, Q.; Qian, Q.; Wei, S.Z.; Yu, L.K. CYP1A1 MspI and exon7 gene polymorphisms and lung cancer risk: an updated meta-analysis and review. J. Exp. Clin. Cancer Res., 2011, 30, 99.
38. Swinney, R.M.; Beuten, J.; Collier, A.B. 3rd; Chen, T.T.; Winick, N.J.; Pollock, B.H.; Tomlinson, G.E. Polymorphisms in CYP1A1 and ethnic-specific susceptibility to acute lymphoblastic leukemia in children. Cancer Epidemiol. Biomarkers Prev., 2011, 20(7), 1537-1542.
39. Bailey, L.R.; Roodi, N.; Dupont, W.D.; Parl, F.F. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res., 1998, 58, 5038-5041.
40. Landi, M.T.; Bergen, A.W.; Baccarelli, A.; Patterson, D.G. Jr.; Grassman, J.; Ter-Minassian, M.; Mocarelli, P.; Caporaso, N.; Masten, S.A.; Pesatori, A.C.; Pittman, G.S.; Bell, D.A. CYP1A1 and CYP1B1 genotypes, haplotypes, and TCDD-induced gene expression in subjects from Seveso, Italy. Toxicology, 2005, 207(2), 191-202.
41. Stoilov, I.; Akarsu, A.N.; Alozie, I.; Child, A.; Barsoum-Homsy, M.; Turacli, M.E.; Or, M.; Lewis, R.A.; Ozdemir, N.; Brice, G.; Aktan, S.G.; Chevrette, L.; Coca-Prados, M.; Sarfarazi, M. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am. J. Hum. Genet., 1998, 62(3), 573-584.
42. Bandiera, S.; Weidlich, S.; Harth, V.; Broede, P.; Ko, Y.; Friedberg, T. Proteasomal degradation of human CYP1B1: effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol. Pharmacol., 2005, 67(2), 435-443.
43. Gajjar, K.; Martin-Hirsch, P.L.; Martin, F.L. CYP1B1 and hormone-induced cancer. Cancer Lett., 2012, 324(1), 13-30.
44. Shimada, T.; Yun, C.H.; Yamazaki, H.; Gautier, J.C.; Beaune, P.H.; Guengerich, F.P. Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. Mol. Pharmacol., 1992, 41(5), 856-864.
45. Shimada, T.; Hayes, C.L.; Yamazaki, H.; Amin, S.; Hecht, S.S.; Guengerich, F.P.; Sutter, T.R. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res., 1996, 56(13), 2979-2984.
46. Palackal, N.T.; Burczynski, M.E.; Harvey, R.G.; Penning, T.M. The ubiquitous aldehyde reductase (AKR1A1) oxidizes proximate carcinogen trans-dihydrodiols to o-quinones: potential role in polycyclic aromatic hydrocarbon activation. Biochemistry (Mosc). 2001, 40(36), 10901-10910.
47. Park, J.H.; Mangal, D.; Tacka, K.A.; Quinn, A.M.; Harvey, R.G.; Blair, I.A.; Penning, T.M. Evidence for the aldo-keto reductase pathway of polycyclic aromatic trans-dihydrodiol activation in human lung A549 cells. Proc. Natl. Acad. Sci. U. S. A., 2008, 105(19), 6846-6851.
48. Hu, X.; Srivastava, S.K.; Xia, H.; Awasthi, Y.C.; Singh, S.V. An alpha class mouse glutathione S-transferase with exceptional catalytic efficiency in the conjugation of glutathione with 7beta, 8alpha-dihydroxy-9alpha,10alpha-oxy-7,8,9,10-tetrahydrobenzo(a)pyrene. J. Biol. Chem., 1996, 271(51), 32684-32688.
49. Cavalieri, E.L.; Rogan, E.G. The approach to understanding aromatic hydrocarbon carcinogenesis. The central role of radical cations in metabolic activation. Pharmacol. Ther., 1992, 55(2), 183-199.
50. Shimada, T.; Gillam, E.M.; Oda, Y.; Tsumura, F.; Sutter, T.R.; Guengerich, F.P.; Inoue, K. Metabolism of benzo[a]pyrene to trans-7,8-dihydroxy-7, 8-dihydrobenzo[a]pyrene by recombinant human cytochrome P450 1B1 and purified liver epoxide hydrolase. Chem. Res. Toxicol., 1999, 12(7), 623-629.
51. Shimada, T.; Yamazaki, H.; Mimura, M.; Wakamiya, N.; Ueng, Y.F.; Guengerich, F.P.; Inui, Y. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab. Dispos., 1996, 24(5), 515-522.
52. Zhang, L.; Jin, Y.; Chen, M.; Huang, M.; Harvey, R.G.; Blair, I.A.; Penning, T.M. Detoxication of structurally diverse polycyclic aromatic hydrocarbon (PAH) o-quinones by human recombinant catechol-O-methyltransferase (COMT) via O-methylation of PAH catechols. J. Biol. Chem., 2011, 286(29), 25644-25654.
53. Lee, A.J.; Cai, M.X.X.; Thomas, P.E.; Conney, A.H.; Zhu, B.T. Characterization of the oxidative metabolites of 17 beta-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms. Endocrinology, 2003, 144(8), 3382-3398.
54. Badawi, A.F.; Cavalieri, E.L.; Rogan, E.G. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alphahydroxylation of 17beta-estradiol. Metabolism, 2001, 50(9), 1001-1003.
55. Lee, A.J.; Cai, M.X.; Thomas, P.E.; Conney, A.H.; Zhu, B.T. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology, 2003, 144(8), 3382-3398.
56. Van Aswegen, C.H.; Purdy, R.H.; Wittliff, J.L. Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers. J. Steroid Biochem., 1989, 32(4), 485-492.
57. Cavalieri, E.; Frenkel, K.; Liehr, J.G.; Rogan, E.; Roy, D. Estrogens as endogenous genotoxic agents--DNA adducts and mutations. J. Natl. Cancer Inst. Monogr., 2000(27), 75-93.
58. Hanna, I.H.; Dawling, S.; Roodi, N.; Guengerich, F.P.; Parl, F.F. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res., 2000, 60(13), 3440-3444.
59. Uno, S.; Dalton, T.P.; Dragin, N.; Curran, C.P.; Derkenne, S.; Miller, M.L.; Shertzer, H.G.; Gonzalez, F.J.; Nebert, D.W. Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol. Pharmacol., 2006, 69(4), 1103-1114.
60. Uno, S.; Dalton, T.P.; Shertzer, H.G.; Genter, M.B.; Warshawsky, D.; Talaska, G.; Nebert, D.W. Benzo[a]pyrene-induced toxicity: paradoxical protection in Cyp1a1(-/-) knockout mice having increased hepatic BaP-DNA adduct levels. Biochem. Biophys. Res. Commun., 2001, 289(5), 1049-1056.
61. Uno, S.; Dalton, T.P.; Derkenne, S.; Curran, C.P.; Miller, M.L.; Shertzer, H.G.; Nebert, D.W. Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol. Pharmacol., 2004, 65(5), 1225-1237.
62. Fang, C.; Zhang, Q.Y. The role of small-intestinal P450 enzymes in protection against systemic exposure of orally administered benzo[a]pyrene. J. Pharmacol. Exp. Ther., 2010, 334(1), 156-163.
63. Shi, Z.; Dragin, N.; Galvez-Peralta, M.; Jorge-Nebert, L.F.; Miller, M.L.; Wang, B.; Nebert, D.W. Organ-specific roles of CYP1A1 during detoxication of dietary benzo[a]pyrene. Mol. Pharmacol., 2010, 78(1), 46-57.
64. Laroche-Clary, A.; Le Morvan, V.; Yamori, T.; Robert, J. Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studies with in vitro models. Mol. Cancer Ther., 2010, 9(12), 3315-3321.
65. Heubner, M.; Wimberger, P.; Riemann, K.; Kasimir-Bauer, S.; Otterbach, F.; Kimmig, R.; Siffert, W. The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms. Oncol. Res., 2010, 18(7), 343-347.
66. Rochat, B.; Zoete, V.; Grosdidier, A.; von Grunigen, S.; Marull, M.; Michielin, O. In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1. Biopharm. Drug Dispos., 2008, 29(2), 103-118.
67. Rochat, B.; Morsman, J.M.; Murray, G.I.; Figg, W.D.; McLeod, H.L. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J. Pharmacol. Exp. Ther., 2001, 296(2), 537-541.
68. Pastina, I.; Giovannetti, E.; Chioni, A.; Sissung, T.M.; Crea, F.; Orlandini, C.; Price, D.K.; Cianci, C.; Figg, W.D.; Ricci, S.; Danesi, R. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. BMC Cancer, 2010, 10, 511.
69. Crewe, H.K.; Notley, L.M.; Wunsch, R.M.; Lennard, M.S.; Gillam, E.M. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and Ndesmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. and Dispos., 2002, 30(8), 869-874.
70. Androutsopoulos, V.P.; Papakyriakou, A.; Vourloumis, D.; Spandidos, D.A. Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids. Bioorg. Med. Chem., 2011, 19(9), 2842-2849.
71. Jones, B.C.; Middleton, D.S.; Youdim, K. Cytochrome P450 metabolism and inhibition: analysis for drug discovery. Prog. Med. Chem., 2009, 47, 239-263.
72. Sangamwar, A.T.; Labhsetwar, L.B.; von Kuberkar, S. Exploring CYP1A1 as anticancer target: homology modeling and in silico inhibitor design. J. Mol. Model, 2008, 14(11), 1101-1109.
73. Takemura, H.; Uchiyama, H.; Ohura, T.; Sakakibara, H.; Kuruto, R.; Amagai, T.; Shimoi, K. A methoxyflavonoid, chrysoeriol, selectively inhibits the formation of a carcinogenic estrogen metabolite in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol., 2010, 118(1-2), 70-76.
74. Androutsopoulos, V.P.; Papakyriakou, A.; Vourloumis, D.; Tsatsakis, A.M.; A. S.D. Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol. Ther., 2010, 126(1), 9-20.
75. Doostdar, H.; Burke, M.D.; Mayer, R.T. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology, 2000, 144(1-3), 31-38.
76. Takemura, H.; Itoh, T.; Yamamoto, K.; Sakakibara, H.; Shimoi, K. Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg. Med. Chem., 2010, 18(17), 6310-6315.
77. Bradshaw, T.D.; Wren, J.E.; Bruce, M.; Barrett, D.A.; Leong, C.O.; Gaskell, M.; Wright, E.K.; Farmer, P.B.; Henderson, C.J.; Wolf, R.; Stevens, M.F. Preclinical toxicokinetic evaluation of phortress [2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole lysylamide dihydrochloride] in two rodent species. Pharmacology, 2009, 83(2), 99-109.
78. Vaupel, P. The role of hypoxia-induced factors in tumor progression. Oncologist, 2004, 9, 10-17.
79. Semenza, G.L. Oxygen sensing, homeostasis, and disease. N. Engl. J. Med., 2011, 365(6), 537-547.
80. Wenger, R.H. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J., 2002, 16(10), 1151-1162.
81. Michaelis, U.R.; Fisslthaler, B.; Barbosa-Sicard, E.; Falck, J.R.; Fleming, I.; Busse, R. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J. Cell Sci., 2005, 118(Pt 23), 5489-5498.
82. Legendre, C.; Hori, T.; Loyer, P.; Aninat, C.; Ishida, S.; Glaise, D.; Lucas-Clerc, C.; Boudjema, K.; Guguen-Guillouzo, C.; Corlu, A.; Morel, F. Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression. Eur. J. Cancer, 2009, 45(16), 2882-2892.
83. Yang, B.; Graham, L.; Dikalov, S.; Mason, R.P.; Falck, J.R.; Liao, J.K.; Zeldin, D.C. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol. Pharmacol., 2001, 60(2), 310-320.
84. Akiyama, T.E.; Gonzalez, F.J. Regulation of P450 genes by liverenriched transcription factors and nuclear receptors. Biochim. Biophys. Acta, 2003, 1619(3), 223-234.
85. Pascussi, J.M.; Gerbal-Chaloin, S.; Drocourt, L.; Maurel, P.; Vilarem, M.J. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta, 2003, 1619(3), 243-253.
86. Jover, R.; Moya, M.; Gomez-Lechon, M.J. Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha. Curr. Drug Metab., 2009, 10(5), 508-519.
87. Rizzo, G.; Renga, B.; Mencarelli, A.; Pellicciari, R.; Fiorucci, S. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr. Drug Targets Endocr. Metabol. Disord., 2005, 5(3), 289-303.
88. Zhang, N.; Walker, M.K. Crosstalk between the aryl hydrocarbon receptor and hypoxia on the constitutive expression of cytochrome P4501A1 mRNA. Cardiovasc. Toxicol., 2007, 7(4), 282-290.
89. Alfieri, R.R.; Galetti, M.; Tramonti, S.; Andreoli, R.; Mozzoni, P.; Cavazzoni, A.; Bonelli, M.; Fumarola, C.; La Monica, S.; Galvani, E.; De Palma, G.; Mutti, A.; Mor, M.; Tiseo, M.; Mari, E.; Ardizzoni, A.; Petronini, P.G. Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines. Mol. Cancer, 2011, 10, 143.
90. Nishida, C.R.; Lee, M.; de Montellano, P.R.O. Efficient Hypoxic Activation of the Anticancer Agent AQ4N by CYP2S1 and CYP2W1. Mol. Pharmacol., 2010, 78(3), 497-502.
91. Semenza, G.L. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell, 2001, 107(1), 1-3.
92. Chan, W.K.; Yao, G.; Gu, Y.Z.; Bradfield, C.A. Cross-talk between the aryl hydrocarbon receptor and hypoxia inducible factor signaling pathways. Demonstration of competition and compensation. J. Biol. Chem., 1999, 274(17), 12115-12123.
93. Semenza, G.L. Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance. J. Clin. Invest., 2001, 108(1), 39-40.
94. Webler, A.C.; Michaelis, U.R.; Popp, R.; Barbosa-Sicard, E.; Murugan, A.; Falck, J.R.; Fisslthaler, B.; Fleming, I. Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. Am. J. Physiol.-Cell Ph., 2008, 295(5), C1292-C1301.
95. Reihill, J.A.; Ewart, M.A.; Hardie, D.G.; Salt, I.P. AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production. Biochem. Biophys. Res. Commun., 2007, 354(4), 1084-1088.
96. Hardie, D.G.; Sakamoto, K. AMPK: a key sensor of fuel and energy status in skeletal muscle. Physiology (Bethesda), 2006, 21, 48-60.
97. Oguro, A.; Sakamoto, K.; Funae, Y.; Imaoka, S. Overexpression of CYP3A4, but not of CYP2D6, Promotes Hypoxic Response and Cell Growth of Hep3B Cells. Drug Metab. Pharmacok., 2011, 26(4), 407-415.
98. Suzuki, S.; Oguro, A.; Osada-Oka, M.; Funae, Y.; Imaoka, S. Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells. J. Pharmacol. Sci., 2008, 108(1), 79-88.
99. du Souich, P.; Fradette, C. The effect and clinical consequences of hypoxia on cytochrome P450, membrane carrier proteins activity and expression. Expert Opin. Drug. Met., 2011, 7(9), 1083-1100.
100. Isin, E.M.; Guengerich, F.P. Complex reactions catalyzed by cytochrome P450 enzymes. Biochim. Biophys. Acta, 2007, 1770(3), 314-329.
101. Chae, Y.H.; Thomas, T.; Guengerich, F.P.; Fu, P.P.; El-Bayoumy, K. Comparative metabolism of 1-, 2-, and 4-nitropyrene by human hepatic and pulmonary microsomes. Cancer Res., 1999, 59(7), 1473-1480.
102. Levova, K.; Moserova, M.; Kotrbova, V.; Sulc, M.; Henderson, C.J.; Wolf, C.R.; Phillips, D.H.; Frei, E.; Schmeiser, H.H.; Mares, J.; Arlt, V.M.; Stiborova, M. Role of Cytochromes P450 1A1/2 in Detoxication and Activation of Carcinogenic Aristolochic Acid I: Studies with the Hepatic NADPH:Cytochrome P450 Reductase Null (HRN) Mouse Model. Toxicol. Sci., 2011, 121(1), 43-56.
103. Chen, Y.; Hu, L.Q. Design of Anticancer Prodrugs for Reductive Activation. Med. Res. Rev., 2009, 29(1), 29-64.
104. Patterson, L.H. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab. Rev., 2002, 34(3), 581-592.
105. Anderson, R.F.; Harris, T.A.; Hay, M.P.; Denny, W.A. Enhanced conversion of DNA radical damage to double strand breaks by 1,2,4-benzotriazine 1,4-dioxides linked to a DNA binder compared to tirapazamine. Chem. Res. Toxicol., 2003, 16(11), 1477-1483.
106. Patterson, A.V.; Saunders, M.P.; Chinje, E.C.; Patterson, L.H.; Stratford, I.J. Enzymology of tirapazamine metabolism: a review. Anticancer Drug Des., 1998, 13(6), 541-573.
107. Anderson, R.F.; Shinde, S.S.; Hay, M.P.; Gamage, S.A.; Denny, W.A. Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J. Am. Chem. Soc., 2003, 125(3), 748-756.
108. Shinde, S.S.; Anderson, R.F.; Hay, M.P.; Gamage, S.A.; Denny, W.A. Oxidation of 2-deoxyribose by benzotriazinyl radicals of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides. J. Am. Chem. Soc., 2004, 126(25), 7865-7874.
109. Biedermann, K.A.; Wang, J.; Graham, R.P.; Brown, J.M. SR 4233 cytotoxicity and metabolism in DNA repair-competent and repairdeficient cell cultures. Br. J. Cancer, 1991, 63(3), 358-362.
110. Laderoute, K.R.; Rauth, A.M. Identification of two major reduction products of the hypoxic cell toxin 3-amino-1,2,4-benzotriazine-1,4-dioxide. Biochem. Pharmacol., 1986, 35(19), 3417-3420.
111. Laderoute, K.; Wardman, P.; Rauth, A.M. Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233). Biochem. Pharmacol., 1988, 37(8), 1487-1495.
112. Rischin, D.; Peters, L.J.; O'Sullivan, B.; Giralt, J.; Fisher, R.; Yuen, K.; Trotti, A.; Bernier, J.; Bourhis, J.; Ringash, J.; Henke, M.; Kenny, L. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J. Clin. Oncol., 2010, 28(18), 2989-2995.
113. Hicks, K.O.; Pruijn, F.B.; Secomb, T.W.; Hay, M.P.; Hsu, R.; Brown, J.M.; Denny, W.A.; Dewhirst, M.W.; Wilson, W.R. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J. Natl. Cancer Inst., 2006, 98(16), 1118-1128.
114. Hicks, K.O.; Siim, B.G.; Jaiswal, J.K.; Pruijn, F.B.; Fraser, A.M.; Patel, R.; Hogg, A.; Liyanage, H.D.; Dorie, M.J.; Brown, J.M.; Denny, W.A.; Hay, M.P.; Wilson, W.R. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin. Cancer Res., 2010, 16(20), 4946-4957.
115. Denny, W.A. Prodrug strategies in cancer therapy. Eur. J. Med. Chem., 2001, 36(7-8), 577-595.
116. McCarthy, H.O.; Yakkundi, A.; McErlane, V.; Hughes, C.M.; Keilty, G.; Murray, M.; Patterson, L.H.; Hirst, D.G.; McKeown, S.R.; Robson, T. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther., 2003, 10(1), 40-48.
117. Yakkundi, A.; McErlane, V.; Murray, M.; McCarthy, H.O.; Ward, C.; Hughes, C.M.; Patterson, L.H.; Hirst, D.G.; McKeown, S.R.; Robson, T. Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Ther., 2006, 13(6), 598-605.
118. Williams, K.J.; Albertella, M.R.; Fitzpatrick, B.; Loadman, P.M.; Shnyder, S.D.; Chinje, E.C.; Telfer, B.A.; Dunk, C.R.; Harris, P.A.; Stratford, I.J. In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts. Mol. Cancer Ther., 2009, 8(12), 3266-3275.
119. Cowen, R.L.; Garside, E.J.; Fitzpatrick, B.; Papadopoulou, M.V.; Williams, K.J. Gene therapy approaches to enhance bioreductive drug treatment. Br. J. Radiol., 2008, 81(1), S45-S56.
120. Swanson, H.I.; Njar, V.C.; Yu, Z.; Castro, D.J.; Gonzalez, F.J.; Williams, D.E.; Huang, Y.; Kong, A.N.; Doloff, J.C.; Ma, J.; Waxman, D.J.; Scott, E.E. Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy. Drug Metab. Dispos., 2010, 38(4), 539-544.
121. McErlane, V.; Yakkundi, A.; McCarthy, H.O.; Hughes, C.M.; Patterson, L.H.; Hirst, D.G.; Robson, T.; McKeown, S.R. A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N. J. Gene Med., 2005, 7(7), 851-859.
122. Smith, P.J.; Desnoyers, R.; Blunt, N.; Giles, Y.; Patterson, L.H.; Watson, J.V. Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation. Cytometry, 1997, 27(1), 43-53.
123. Chen, L.; Yu, L.J.; Waxman, D.J. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res., 1997, 57(21), 4830-4837.
124. Raccor, B.S.; Claessens, A.J.; Dinh, J.C.; Park, J.R.; Hawkins, D.S.; Thomas, S.S.; Makar, K.W.; McCune, J.S.; Totah, R.A. Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo. Drug Metab. Dispos., 2012, 40(1), 54-63.
125. Panigrahy, D.; Kaipainen, A.; Greene, E.R.; Huang, S. Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metast. Rev., 2010, 29(4), 723-735.
126. Lee, C.A.; Neul, D.; Clouser-Roche, A.; Dalvie, D.; Wester, M.R.; Jiang, Y.; Jones, J.P. 3rd; Freiwald, S.; Zientek, M.; Totah, R.A. Identification of novel substrates for human cytochrome P450 2J2. Drug Metab. Dispos., 2010, 38(2), 347-356.
127. Lee, C.A.; Jones, J.; Katayama, J.; Kaspera, R.; Jiang, Y.; Freiwald, S.; Smith, E.; Walker, G.; Totah, R.A. Identifying a Selective Substrate and Inhibitor Pair for the Evaluation of CYP2J2 Activity. Drug Metab. Dispos., 2012, 40(5), 943-951.
128. Berlin, D.S.; Sangkuhl, K.; Klein, T.E.; Altman, R.B. PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2. Pharmacogenet. Genom., 2011, 21(5), 308-311.
129. Xu, X.; Zhang, X.A.; Wang, D.W. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv. Drug Deliv. Rev., 2011, 63(8), 597-609.
130. Kaspera, R.; Totah, R.A. Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology. Expert Opin. Drug Metab. Toxicol., 2009, 5(7), 757-771.
131. Sato, M.; Yokoyama, U.; Fujita, T.; Okumura, S.; Ishikawa, Y. The roles of cytochrome p450 in ischemic heart disease. Curr. Drug Metab., 2011, 12(6), 526-532.
132. Lee, A.C.; Murray, M. Up-regulation of human CYP2J2 in HepG2 cells by butylated hydroxyanisole is mediated by c-Jun and Nrf2. Mol. Pharmacol., 2010, 77(6), 987-994.
133. Zhang, Y.; El-Sikhry, H.; Chaudhary, K.R.; Batchu, S.N.; Shayeganpour, A.; Jukar, T.O.; Bradbury, J.A.; Graves, J.P.; DeGraff, L.M.; Myers, P.; Rouse, D.C.; Foley, J.; Nyska, A.; Zeldin, D.C.; Seubert, J.M. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am. J. Physiol. Heart Circ. Physiol., 2009, 297(1), H37-46.
134. Chen, F.; Chen, C.; Yang, S.; Gong, W.; Wang, Y.; Cianflone, K.; Tang, J.; Wang, D.W. Let-7b inhibits human cancer phenotype by targeting cytochrome P450 epoxygenase 2J2. PLoS One, 2012, 7(6), e39197.
135. Jiang, J.G.; Fu, X.N.; Chen, C.L.; Wang, D.W. Expression of cytochrome P450 arachidonic acid epoxygenase 2J2 in human tumor tissues and cell lines. Ai Zheng, 2009, 28(2), 93-96.
136. Mitra, R.; Guo, Z.; Milani, M.; Mesaros, C.; Rodriguez, M.; Nguyen, J.; Luo, X.; Clarke, D.; Lamba, J.; Schuetz, E.; Donner, D.B.; Puli, N.; Falck, J.R.; Capdevila, J.; Gupta, K.; Blair, I.A.; Potter, D.A. CYP3A4 mediates growth of estrogen receptorpositive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (+/-)-14,15-epoxyeicosatrienoic acid (EET). J. Biol. Chem., 2011, 286(20), 17543-17559.
137. Panigrahy, D.; Greene, E.R.; Pozzi, A.; Wang, D.W.; Zeldin, D.C. EET signaling in cancer. Cancer Metast. Rev., 2011, 30(3-4), 525-540.
138. Pozzi, A.; Popescu, V.; Yang, S.; Mei, S.; Shi, M.; Puolitaival, S.M.; Caprioli, R.M.; Capdevila, J.H. The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated. J. Biol. Chem., 2010, 285(17), 12840-12850.
139. Chen, C.; Li, G.; Liao, W.; Wu, J.; Liu, L.; Ma, D.; Zhou, J.; Elbekai, R.H.; Edin, M.L.; Zeldin, D.C.; Wang, D.W. Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J. Pharmacol. Exp. Ther., 2009, 329(3), 908-918.
140. Chen, C.; Wei, X.; Rao, X.; Wu, J.; Yang, S.; Chen, F.; Ma, D.; Zhou, J.; Dackor, R.T.; Zeldin, D.C.; Wang, D.W. Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth. J. Pharmacol. Exp. Ther., 2011, 336(2), 344-355.
141. Park, S.W.; Heo, D.S.; Sung, M.W. The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells. Cell Oncol. (Dordr), 2012, 35(1), 1-8.